School of Medicine
Showing 451-500 of 941 Results
-
Tracey McLaughlin
Professor of Medicine (Endocrinology)
Current Research and Scholarly InterestsDr. McLaughlin conducts clinical research related to obesity, insulin resistance, diabetes, and cardiovascular disease (CVD). Current studies include: 1) the impact of macronutrient composition on metabolism, DM2 and CVD; 2) comparison of different weight loss diets on metabolism and CVD risk reduction ; 3) role of adipocytes and adipose tissue immune cells in modulating insulin resistance; 4) use of continuous glucose monitoring and multi-omics to define metabolic phenotype and precision diets
-
Carmen McLean
Clinical Professor (Affiliated), Psych/General Psychiatry and Psychology (Adult)
BioCarmen McLean, PhD, is a clinical psychologist and researcher with the Dissemination and Training Division of the National Center for PTSD at the Palo Alto VA Health Care System. Dr. McLean’s research focuses on increasing the implementation and reach of evidence-based treatments for posttraumatic stress disorder (PTSD).
-
Uel Jackson McMahan
Professor of Neurobiology and of Structural Biology, Emeritus
Current Research and Scholarly InterestsWe are currently investigating mechanisms involved in synaptic transmission and synaptogenesis using electron microscope tomography in ways that provide in situ 3D structural information at macromolecular resolution.
-
Jennifer A McNab
Associate Professor (Research) of Radiology (Radiological Sciences Laboratory)
Current Research and Scholarly InterestsMy research is focused on developing magnetic resonance imaging (MRI) methods that probe brain tissue microstructure. This requires new MRI contrast mechanisms, strategic encoding and reconstruction schemes, physiological monitoring, brain tissue modeling and validation. Applications of these methods include neuronavigation, neurosurgical planning and the development of improved biomarkers for brain development, degeneration, disease and injury.
-
M Windy McNerney, PhD
Clinical Associate Professor (Affiliated), Psych/General Psychiatry and Psychology (Adult)
Staff, Psychiatry and Behavioral SciencesBioDr. M. Windy McNerney is the Director of Biological Sciences for the MIRECC at the Department of Veterans Affairs in Palo Alto, and a Clinical Associate Professor (Affiliated) at Psychiatry and Behavioral Sciences at Stanford School of Medicine. Dr. McNerney holds a particular passion for not only understanding the neurophysiology and biochemistry of mental health diseases, but also advocating for these invisible diseases. Her research focuses on neurodegeneration, depression, TBI, PTSD, and addiction. She is collaborating with researchers to integrate brain imaging and biochemical markers in hopes to better understand these diseases. She also is taking a lead role at the VA in investigating the biochemistry of magnetic brain stimulation and is the leader of the NeuroNado Laboratory. At Stanford University, she is the professor of two popular courses examining the biological and societal issues surrounding substance use disorder, with a major focus on opioids such as fentanyl. She has individually mentored over 25 students from underrepresented groups in STEM activities and leads monthly seminars aimed at facilitating career development. In her free time, she is a community advocate for the treatment of mental health and educates groups about the dangers of fentanyl.
She earned her BS from UC Davis and her PhD from the University of Notre Dame. While at ND, she interned at NASA Ames on Human Factors Engineering. She then went on to a postdoctoral position at Lawrence Livermore National Laboratory (DOE), and then completed a fellowship at the WRIISC program at the VA and Stanford University.
Selected Publications:
McNerney MW, Gurkoff G, Berryhill M (2023). The rehabilitation potential of neurostimulation for mild traumatic brain injury in animal and human studies. Brain Sciences, 13, 1402.
McNerney MW, Kraybill EP Narayanan S, Mojabi F, Venkataramanan V, Heath A (2023). Memory-related hippocampal brain-derived neurotrophic factor activation pathways from repetitive transcranial magnetic stimulation in the 3xTg-AD mouse line. Experimental Gerontology, 183, 11323.
Shuken, S, McNerney MW (2023). Cost and benefits for popular p-value correction methods I three models of quantitative omic experiments. Analytical Chemistry, 95, 2732.
McNerney MW, Heath A, Narayanan S, Yesavage J (2022). Repetitive transcranial magnetic stimulation improves brain-derived neurotrophic factor and cholinergic signaling in the 3xTgAD mouse model of Alzheimer’s disease. Journal of Alzheimer’s Disease, 86, 499..
Heath AM, Brewer M, Yesavage J, McNerney MW. (2021). Improved object recognition memory using post-encoding repetitive transcranial magnetic stimulation. Brain Stimulation, 15, 78.
Yang AC, Vest RT, Kern F, Lee DP, Agam M, Maat CA, Losada PM, Chen MB, Schaum N, Khoury N, Toland A, Calcuttawala K, Shin H, Palovics R, Shin A, Wang EY, Luo J, Gate D, Schultz-Schaeffer WJ, Chu P, Siegenthalar J, McNerney MW, Keller A, Wyss-Coray T (2022). A human brain vascular atlas reveals diverse mediators or Alzheimer’s disease. Nature, 603, 885.
McNerney MW, Hobday T, Cole B, Ganong R, Winas N, Matthews D, Hood J, Lane S (2019). Objective classification of mTBI using machine learning on a combination of frontal electroencephalography measurements and self-reported symptoms. Sports Medicine Open, 4, 14.
McNerney MW, Sheng T, Nechvatal JM, Lee A, Lyons D, Adamson M (2018). Integration of neural and epigenetic contributions to posttraumatic stress symptoms: The role of hippocampal volume and glucocorticoid receptor gene methylation. PLOSONE, e0192222.
Bennion BJ, Be NA, McNerney MW, Lao V, Carlson E, Valdez CA (2017). Predicting a drug’s membrane permeability: A computational model validated with in vitro permeability assay data. Journal of Physical Chemistry, B, 121, 5228.
See more publications at: https://www.ncbi.nlm.nih.gov/pubmed/?term=McNerney%20MW%5BAuthor%5D&cauthor=true&cauthor_uid=17107728 -
Kimford Meador, MD
Professor of Neurology and Neurological Sciences (Adult Neurology)
BioDr. Meador is a Professor of Neurology and Neurosciences at Stanford University, and Clinical Director, Stanford Comprehensive Epilepsy Center. Dr. Meador graduated from the Georgia Institute of Technology in Applied Biology (with high honor) and received his MD from the Medical College of Georgia. After an internship at the University of Virginia and service as an officer in the Public Health Corps, he completed a residency in Neurology at the Medical College of Georgia and a fellowship in Behavioral Neurology at the University of Florida. Dr. Meador joined the faculty at the Medical College of Georgia (1984-2002) where he became the Charbonnier Professor of Neurology. He was the Chair of Neurology at Georgetown University (2002-2004), the Melvin Greer Professor of Neurology and Neuroscience at the University of Florida (2004-2008) where he served as Director of Epilepsy Program and Director of the Clinical Alzheimer Research Program, and Professor of Neurology and Pediatrics at Emory University (2008-2013) where he served as Director of Epilepsy and of Clinical Neurocience Research. He joined the faculty of Stanford University in 2013. Dr. Meador has authored over 400 peer-reviewed publications. His research interests include: cognitive mechanisms (e.g., memory and attention); cerebral lateralization; pharmacology and physiology of cognition; mechanisms of perception, consciousness and memory; EEG; epilepsy; epilepsy and pregnancy; preoperative evaluation for epilepsy surgery; intracarotid amobarbital procedure (i.e., Wada test); functional imaging; therapeutic drug trials; neurodevelopmental effects of antiepileptic drugs; psychoimmunology; behavioral disorders (e.g., aphasia, neglect, dementia); and neuropsychiatric disorders. Dr. Meador has served as the PI for a long running NIH multicenter study of pregnancy outcomes in women with epilepsy and their children. Dr. Meador has served on the editorial boards for Clinical Neurophysiology, Epilepsy and Behavior, Epilepsy Currents, Journal of Clinical Neurophysiology, Neurology, Cognitive and Behavioral Neurology, and Epilepsy.com. His honors include Resident Teaching Award Medical College of Georgia; Outstanding Young Faculty Award in Clinical Sciences Medical College of Georgia; Distinguished Faculty Award for Clinical Research Medical College of Georgia Lawrence C. McHenry History Award American Academy of Neurology; Dreifuss Abstract Award American Epilepsy Society; Fellow of the American Neurological Association; Diplomat of American Neurologic Association; past Chair of the Section of Behavioral Neurology of American Academy of Neurology; past President of Society for Cognitive and Behavioral Neurology; past President of the Society for Behavioral & Cognitive Neurology; past President of the Southern EEG & Epilepsy Society; ranking in the top 10 experts in epilepsy worldwide by Expertscape; Distinguished Alumnus Award for Professional Achievement, Medical College of Georgia, Georgia Regents University 2015; American Epilepsy Society Clinical Research Award; and named award by the American Epilepsy Society: “Kimford J. Meador Research in Women with Epilepsy Award,” and ranked in the top 500 neuroscientist in the world and top 300 in USA by Research.com in 2022.
-
Peter Meaney
Clinical Professor, Pediatrics - Critical Care
Current Research and Scholarly InterestsDr. Meaney is a nationally and internationally recognized pediatric resuscitation scientist, and his current focus is on improving care for seriously ill children at the community clinic and district hospital level in low and middle income countries. Dr Meaney seeks to conduct the necessary research to pioneer, implement and evaluate innovative yet relevant and practical solutions to improve the quality of care for seriously ill or injured children worldwide.
-
Rishi Mediratta
Clinical Associate Professor, Pediatrics
Current Research and Scholarly InterestsI have developed a new promising neonatal mortality prediction score at the University of Gondar Neonatal Intensive Care Unit (NICU) in Gondar, Ethiopia. The score predicts approximately 84% of neonatal deaths in the NICU using clinical variables. I have a dataset over 800 NICU admissions in Gondar. I am recruiting scholars who are interested in conducting clinical and epidemiological research to validate, refine, and implement the mortality score to reduce neonatal mortality in Ethiopia.
-
Natalia Medvedeva
Clinical Assistant Professor, Medicine - Infectious Diseases
BioDr Natalia Medvedeva specializes in the treatment of infectious diseases. She has a special interest in antimicrobial stewardship and medical education.
-
Eric Meffre
Professor of Medicine (Immunology and Rheumatology)
BioDr. Meffre obtained his PhD in Immunology from the Université d’Aix-Marseille in France before he moved to the USA as a postdoc fellow in the laboratory of Dr. Michel Nussenzweig at The Rockefeller University in New York City. He became an assistant professor at Cornell University in 2003 before being recruited at Yale University as associate professor in 2009. He was tenured at Yale in 2014 before he joined the Department of Medicine/Division of Immunology and Rheumatology at Stanford University as a tenured full professor in 2022.
Dr. Meffre’s work focuses on the etiology of autoimmune syndromes and the roles played by B cells in these diseases. His group characterized the abnormal selection of developing autoreactive B cells in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), multiple sclerosis (MS) and Sjögren’s syndrome, resulting in large numbers of autoreactive naïve B cells accumulating in the patient’s blood. Hence, these autoreactive B cells may present self-antigens to T cells and initiate autoimmune diseases. These early B cell tolerance defects are likely primary to these autoimmune diseases and may result from genetic factors such as the 1858T PTPN22 allele that segregates with RA, SLE and T1D and correlate with an impaired removal of developing autoreactive B cells.
His research goals also consist in characterizing the molecules and pathways involved in the establishment of B cell tolerance and the removal of developing autoreactive B cells generated by random V(D)J recombination through the investigation of rare patients with primary immunodeficiency (PID) enrolled through an international network. Alteration of B cell receptor (BCR) or Toll-like receptor (TLR) signaling in PID patients results in a defective central B cell tolerance and a failure to counterselect developing autoreactive B cells in the bone marrow. In contrast, functional and suppressive regulatory T cells play a key role in preventing the accumulation of autoreactive clones in the mature naïve B cell compartment. The recent development of humanized mouse models recapitulating early B cell tolerance checkpoints and their defects in autoimmune settings allow further in-depth investigation of tolerance mechanisms and the development of novel approaches to restore defective central and peripheral B cell tolerance checkpoints and thwart autoimmunity. -
Jessica Lee Mega
Affiliate, Medicine - Med/Cardiovascular Medicine
BioJessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily and former Chief Medical Officer of Google Life Sciences. She is on the Board of Directors at Boston Scientific, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy. She is a Senior Advisor at SandboxAQ and the Chair of the Investment Committee of the American Heart Association’s GRFW Venture Fund.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies and new medical technologies. She directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative and the Board of Directors at Danaher Corporation.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association and the American College of Cardiology. -
Uchechukwu Megwalu, MD, MPH
Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsOutcomes Research
Health Disparities
Comparative Effectiveness Research
Health Literacy
Head and Neck Cancer Epidemiology
SEER database analysis -
Thulaj Dattatraya Meharwade
Postdoctoral Scholar, Cardiovascular Institute
BioDr. Thulaj Meharwade is a postdoctoral fellow at the Stanford Cardiovascular Institute with research interests in Inflammaging, disease modeling, cellular heterogeneity and drug discovery. Dr. Meharwade received his PhD in Biochemistry from the University of Montreal, after conducting thesis work on signalling and transcriptional mechanisms regulating cell fate heterogeneity and totipotent stem cells.
-
Arnav Mehta, MD, PhD
Adjunct Clinical Assistant Professor, Medicine - Oncology
BioDr. Mehta is a board-certified, fellowship-trained medical oncologist at the Stanford Medicine Cancer Center. He is also an adjunct clinical assistant professor in the gastrointestinal (GI) oncology group of the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Mehta specializes in gastrointestinal cancer, with a particular focus on pancreatic and gastric cancers. He also treats colorectal cancers. His treatment specialties include immunotherapy — helping a patient’s immune system fight cancer — and targeted therapies, which send cancer-fighting drugs to specific cancer cell molecules.
His research interests include understanding why GI cancers resist treatments and identifying new ways to treat these tumors. In particular, he is interested in GI tumor immunology, which focuses on directing a person’s immune system to help destroy cancer cells. He also has a special interest in tumor plasticity, which represents the ability of a tumor cell to evolve and develop resistance to therapies.
Dr. Mehta has earned research awards and grants from organizations including the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), and the National Institutes of Health.
Dr. Mehta has published in many peer-reviewed journals, including Nature, Nature Genetics, Nature Immunology, Nature Medicine, Nature Cancer, Cancer Discovery and Immunity. He has written book chapters on subjects including esophageal and gastric cancer. He has also presented his research on topics including tumor immunology and pancreatic cancer at dozens of symposia and meetings around the country.
Dr. Mehta is a member of the AACR and ASCO. -
Jenny Y. Mei
Clinical Assistant Professor, Obstetrics & Gynecology - Maternal Fetal Medicine
Current Research and Scholarly InterestsPostpartum hypertension
Cardio-obstetrics
Quality improvement
